Oslo,  October 25, 2024: Ultimovacs ASA (https://ultimovacs.com/) ("Ultimovacs")
(OSE  ULTI), a clinical-stage biotechnology company developing immunotherapeutic
cancer  vaccines, today  announced that  the results  from Phase  II FOCUS trial
(NCT05075122
(https://www.globenewswire.com/Tracker?data=bKKMFSBPumiwxqSFnuYBmKZxD6NH5EKEd7Xr
HrBNmhltttJAW4AG12WAsPbF3uNIHSxvyDjS2EgkwfsPeZu0PuupLWN_AF-
9zOnH_uECSHG_6G6dK6RvVnNfhQEg5W4U)) have       been       published       online
(https://www.medrxiv.org/content/10.1101/2024.10.24.24315748v1.full.pdf+html) on
the preprint platform medRxiv.

As                              previously                              reported
(https://www.medrxiv.org/content/10.1101/2024.10.24.24315748v1),   topline  data
readout  demonstrated that adding UV1 to  the standard of care pembrolizumab did
not  lead to clinical benefits in  progression free survival or overall survival
in  the  late-stage  head  and  neck  squamous  cell  carcinoma (HNSCC) patients
recruited  in  the  study.  The  study  therefore  did  not meet its primary and
secondary  endpoints. UV1 continued to demonstrate  a positive safety profile in
line  with other UV1 studies with similar events observed in the control arm and
good tolerability.

                                    ==ENDS==

About FOCUS
The   FOCUS   trial   (First-line   metastatic Or   recurrent   HNSCC/Checkpoint
inhibitor UV1 Study)  is an investigator-sponsored, randomized, open label Phase
II  clinical trial.  The primary  objective of  this study  is to  determine the
clinical  performance  of UV1 vaccination  as  add  on to standard pembrolizumab
treatment  as a  first-line treatment  in metastatic  patients or  a second-line
treatment  in patients with recurrent PD-L1 positive head and neck squamous cell
carcinoma.  Professor Mascha Binder is the principal investigator for the trial,
which  is sponsored  by the  Medical Faculty,  University of Halle-Wittenberg in
Germany.  The first patient in the FOCUS  trial was enrolled in August 2021, and
patients   have   been   treated  at  10 sites  across  Germany.  The  trial  is
investigating  the tolerability and efficacy addition of UV1 to standard of care
treatment    with   programmed   death   receptor-1 (PD   1)-blocking   antibody
pembrolizumab  versus pembrolizumab  monotherapy. The  75 patients indicated for
treatment  with pembrolizumab  have been  randomized 2-to-1 so  that 50 patients
will  receive UV1 and  pembrolizumab and 25 patients  will receive pembrolizumab
alone.  The primary endpoint is PFS  rate at 6 months after first administration
of  study medication. Secondary endpoints include  PFS and OS (overall survival,
by  Kaplan-Meier estimate), objective response  rate (ORR), duration of response
(DOR)  and safety, with minimum 12 months follow-up.  As OS is recognized as the
determining  efficacy  measure  in  guiding  further  development in this cancer
indication,  the topline results will be disclosed 12 months after enrollment of
the last patient, allowing simultaneous disclosure of both PFS and OS.

About UV1
UV1  is a universal cancer vaccine designed to induce a specific T cell response
against  telomerase. UV1  consists of  long, synthetic  peptides, representing a
sequence  in the reverse  transcriptase subunit of  telomerase (hTERT), shown to
induce  CD4+  T  cells.  These  CD4+  T  cells  have  the  potential  to provide
inflammatory  signals and T  cell support that  are believed to  be critical for
triggering a strong anti-tumor immune response. Following intradermal injection,
antigen presenting cells (APCs) in the skin are exposed to the vaccine peptides.
These  APCs will  process the  peptides, and  present vaccine  epitopes on Human
Leukocyte Antigen (HLA) molecules to naïve T cells in the lymph nodes. Activated
vaccine-specific  T cells will  then enter the  circulation and search for cells
displaying their cognate antigen in the context of HLA molecules.

The  UV1 peptides contain several epitopes, shown to be non-restrictive in terms
of  (HLA) alleles for presentation. It is  therefore not required to perform HLA
pre-screening   of   patients,   which   potentially  enables  broad  population
utilization  of  the  vaccine.  UV1  is  administered over three months as eight
intradermal injections together with the immune-modulator, GM-CSF.

About Ultimovacs
Ultimovacs   is   a   clinical-stage   biotechnology  company  developing  novel
immunotherapies  against cancer. The  product candidate UV1  is an off-the-shelf
therapeutic cancer vaccine designed to enhance the benefits of immunotherapy and
improve  cancer treatment efficacy for patients. UV1 triggers an immune response
against  the shared cancer antigen telomerase, a target present in 85-90% of all
cancer indications across disease stages.

Ultimovacs  is investigating  the safety  and efficacy  of UV1 in a wide-ranging
clinical  development program including various cancer indications and different
immunotherapy   combinations.  The  ongoing  Phase  II  program  comprises  five
randomized  clinical  trials  in  melanoma,  mesothelioma, head and neck cancer,
ovarian  cancer, and non-small  cell lung cancer.  More than 640 patients in the
U.S.,  Europe, and  Australia are  being enrolled  in all  Phase I  and Phase II
trials in the current program.

Furthermore,  Ultimovacs is developing a novel conjugation technology, initially
formed  to support the expansion of our  vaccine pipeline. With the objective of
driving  value and future pipeline  growth, this flexible conjugation technology
has  the  potential  to  be  broadly  applicable  to  a  variety  of therapeutic
modalities,  such as  innovative drug  conjugates with favorable pharmacological
properties, and in multiple disease areas.

Ultimovacs is listed on the Euronext Oslo Stock Exchange (OSE:ULTI).

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com (mailto:carlos.desousa@ultimovacs.com)
Phone: +47 908 92507

Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632